Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MNTA
Previous Symbol
CUSIP60877T10
Phone617-491-9700
Debt
Debt-to-Equity RatioN/A
Current Ratio5.40
Quick Ratio5.40
Price-To-Earnings
Trailing P/E Ratio-9.49
Forward P/E Ratio-4.23
P/E GrowthN/A
Sales & Book Value
Annual Sales$138.88 million
Price / Sales8.09
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.90 per share
Price / Book2.32
Profitability
EPS (Most Recent Fiscal Year)($1.20)
Net Income$-88,090,000.00
Net Margins-158.21%
Return on Equity-44.72%
Return on Assets-34.10%
Miscellaneous
Employees279
Outstanding Shares98,610,000
Market Cap$1.10 billion
OptionableOptionable
Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions
What is Momenta Pharmaceuticals' stock symbol?
Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."
How were Momenta Pharmaceuticals' earnings last quarter?
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced its quarterly earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.63) by $0.18. The biotechnology company earned $14.88 million during the quarter, compared to analyst estimates of $16.99 million. Momenta Pharmaceuticals had a negative return on equity of 44.72% and a negative net margin of 158.21%. Momenta Pharmaceuticals's revenue for the quarter was down 38.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.44) EPS. View Momenta Pharmaceuticals' Earnings History.
When is Momenta Pharmaceuticals' next earnings date?
What price target have analysts set for MNTA?
3 equities research analysts have issued twelve-month price targets for Momenta Pharmaceuticals' shares. Their forecasts range from $16.00 to $39.00. On average, they anticipate Momenta Pharmaceuticals' share price to reach $30.00 in the next twelve months. This suggests a possible upside of 163.4% from the stock's current price. View Analyst Price Targets for Momenta Pharmaceuticals.
What is the consensus analysts' recommendation for Momenta Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Momenta Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Momenta Pharmaceuticals.
What are Wall Street analysts saying about Momenta Pharmaceuticals stock?
Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Momenta initiated a strategic review of its ongoing operations with the goal of reducing expenditure on its biosimilar portfolio, which should free up additional capital to fully fund its novel autoimmune portfolio.The company will now advance only two late-stage biosimilar assets, M923, its wholly-owned proposed biosimilar to Humira and M710, its proposed biosimilar to Eylea being developed in collaboration with Mylan. Momenta expects to file a biologics license application (BLA) for M923 with the FDA and plans to work to identify a commercialization partner for this product candidate. Momenta will restructure its executive team and reduce its workforce by approximately 50%. The cost savings from the restructuring plan should enable the company to redirect a meaningful portion of its resources toward novel drug candidates for the treatment of rare, immune-mediated diseases.Shares of the company have outperformed the industry in the year so far." (11/14/2018)
- 2. Stifel Nicolaus analysts commented, "We believe MNTA’s R&D day on 10/11 will be an important event as the company repositions itself as more of a traditional biotech refocusing its resources on its proprietary pipeline. We think management’s recent steps on restructuring is a testament to that and while the outcome of the strategic review did not get many investors excited, we think it was necessary ahead of R&D day. As we indicated in our resumption of coverage, we believe we are making an early call on MNTA given our bullishness on the promise of the FcRn class and think additional data at R&D day for its candidate, M281, could provide some incremental differentiation relative to other programs furthering our thesis it could be best-in-class and could offer modest near-term upside for the stock." (10/10/2018)
Has Momenta Pharmaceuticals been receiving favorable news coverage?
News coverage about MNTA stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Momenta Pharmaceuticals earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the next several days.
Who are some of Momenta Pharmaceuticals' key competitors?
Some companies that are related to Momenta Pharmaceuticals include Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Atara Biotherapeutics (ATRA), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Regenxbio (RGNX), Spark Therapeutics (ONCE), Editas Medicine (EDIT) and Rubius Therapeutics (RUBY).
Who are Momenta Pharmaceuticals' key executives?
Momenta Pharmaceuticals' management team includes the folowing people:
- Mr. Craig A. Wheeler, Pres, CEO & Exec. Director (Age 58)
- Dr. Ganesh Venkataraman Kaundinya, Co-Founder & Consultant (Age 51)
- Dr. Santiago Arroyo M.D., Ph.D., Chief Medical Officer & Sr. VP of Devel.
- Mr. Bruce A. Leicher, Consultant (Age 62)
- Mr. Scott M. Storer, Consultant
Who are Momenta Pharmaceuticals' major shareholders?
Momenta Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.42%), FMR LLC (15.00%), Vanguard Group Inc. (9.67%), Vanguard Group Inc (9.67%), Janus Henderson Group PLC (2.10%) and Renaissance Technologies LLC (1.63%). Company insiders that own Momenta Pharmaceuticals stock include Anthony M Manning, Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Jo Ann Beltramello, Richard P Shea, Santiago Arroyo, Scott M Storer and Young Kwon. View Institutional Ownership Trends for Momenta Pharmaceuticals.
Which institutional investors are selling Momenta Pharmaceuticals stock?
MNTA stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Teachers Advisors LLC, VHCP Management II LLC, Tocqueville Asset Management L.P., Renaissance Technologies LLC, JPMorgan Chase & Co., JPMorgan Chase & Co. and Franklin Resources Inc.. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Anthony M Manning, Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Jo Ann Beltramello, Santiago Arroyo, Scott M Storer and Young Kwon. View Insider Buying and Selling for Momenta Pharmaceuticals.
Which institutional investors are buying Momenta Pharmaceuticals stock?
MNTA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc, Vanguard Group Inc., Putnam Investments LLC, FMR LLC, Morgan Stanley, Bank of New York Mellon Corp and MetLife Investment Advisors LLC. View Insider Buying and Selling for Momenta Pharmaceuticals.
How do I buy shares of Momenta Pharmaceuticals?
Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Momenta Pharmaceuticals' stock price today?
One share of MNTA stock can currently be purchased for approximately $11.39.
How big of a company is Momenta Pharmaceuticals?
Momenta Pharmaceuticals has a market capitalization of $1.10 billion and generates $138.88 million in revenue each year. The biotechnology company earns $-88,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Momenta Pharmaceuticals employs 279 workers across the globe.
What is Momenta Pharmaceuticals' official website?
How can I contact Momenta Pharmaceuticals?
Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]
MarketBeat Community Rating for Momenta Pharmaceuticals (NASDAQ MNTA)
MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe MNTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
